What is Bicara Therapeutics's G&A?

Bicara Therapeutics (BCAX) reported G&A of $12.74M in Q1 2026.

How has Bicara Therapeutics's G&A changed year-over-year?

Bicara Therapeutics's G&A increased by 70.9% year-over-year, from $7.46M to $12.74M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Bicara Therapeutics (BCAX) G&A — Quarterly & Annual

Screener

G&A at other companies

ArriVent BioPharma, Inc.AVBP

$8.49M+54.9%

Arcus BiosciencesRCUS

$24M-17.2%

Inhibrx Biosciences, Inc.INBX

$5.71M-5.2%

ImmunomeIMNM

$12.95M+21.1%

Summit TherapeuticsSMMT

$62.59M+302%

Tyra Biosciences, Inc.TYRA

$8.53M+23.8%

Segments

By segment

See full

Reportable Segment$12.74M+70.9%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.81B+217%

Enterprise value$1.49B+1,000%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed: May 11, 2026, 4:03 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001628280-26-033429

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Operating expenses
Research and development - related party	$1,982	$6,575
Research and development	45,518	27,758
General and administrative	12,742	7,455
Total operating expenses	60,242	41,788
Loss from operations	(60,242)	(41,788)
Other income
Interest income	4,083	5,014

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's G&A?: Bicara Therapeutics (BCAX) reported G&A of $12.74M in Q1 2026.
How has Bicara Therapeutics's G&A changed year-over-year?: Bicara Therapeutics's G&A increased by 70.9% year-over-year, from $7.46M to $12.74M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.